FOLH1 and posterior cortical atrophy: Recently, several studies showed promising results in further comparing RM2-PET and PSMA-PET in patients with biochemical recurrence of prostate cancer [36], in patients with newly diagnosed intermediate- or high-risk prostate cancer [37] and in comparing RM2-PET of PCa with multiparametric magnetic resonance imaging, histopathology, and immunohistochemistry [38].